Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial
Mené sur 87 patients atteints d'un lymphome hodgkinien de stade I-IIA (durée médiane de suivi : 10 ans), cet essai évalue, du point de vue de la survie spécifique et de la survie globale, l'efficacité d'un traitement combinant 8 semaines de chimiothérapie de type Stanford V avec une radiothérapie des champs impliqués
Introduction To assess the efficacy of an abbreviated Stanford V regimen in patients with early-stage Hodgkin lymphoma (HL).Patients and methods Patients with untreated nonbulky stage I–IIA supradiaphragmatic HL were eligible for the G4 study. Stanford V chemotherapy was administered for 8 weeks followed by radiation therapy (RT) 30 Gy to involved fields (IF). Freedom from progression (FFP), disease-specific survival (DSS) and overall survival (OS) were estimated.Results All 87 enrolled patients completed the abbreviated regimen. At a median follow-up of 10 years, FFP, DSS and OS are 94%, 99% and 94%, respectively. Therapy was well tolerated with no treatment-related deaths.Conclusions Mature results of the abbreviated Stanford V regimen in nonbulky early-stage HL are excellent and comparable to the results from other contemporary therapies.